Please login to the form below

MINT

This page shows the latest MINT news and features for those working in and with pharma, biotech and healthcare.

Takeda grows in Turkey with Neutec subsidiary acquisition

Along with fellow MINT bloc countries Mexico, Indonesia and Nigeria, Turkey is considered an attractive market for the pharma industry thanks to its increasingly affluent population and long-term growth potential,

Latest news

Turkey aims to become ‘global player’ in biopharma

As one of the new MINT block of emerging markets (along with Mexico, Indonesia and Nigeria), the country has attracted quite a lot of investment from pharma multinationals, keen to tap
Safety in numbers

The law calls for serialised codes in a 2D datamatrix format which will be printed on self-adhesive security labels supplied by the Brazilian mint.
Survival tactics

Mundipharma International (MINT) and its independent associated companies are perhaps more like an investor with go-to-market capabilities than a traditional pharmaceutical company. ... MINT realised this and moved quickly to facilitate the acquisition
In mint condition

The potential economic benefit of maintaining a healthy workforce should be considered when valuing health technologies
Hospital trust criticised for limiting heart treatment

It is just one way that the private sector makes a mint out of stupid NHS targets.î.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

Turkey: A growing pharma market with huge potential

The Turkish biopharma market offers many opportunities - if it can overcome its sustainability challenge

More from intelligence
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest from PMHub

Deep Dive - MINT: opportunities in ‘frontier’ markets?

What is MINT? An acronym he coined for the ‘frontier’ markets of Mexico, Indonesia, Nigeria and Turkey. ... In our latest article for Pharmaphorum’s Deep Dive magazine Rachel Howard and Sue Rees investigate what the opportunities may be for pharma
Turkey: Identifying the Growth Drivers

Published in eye for pharma 3 April by Marc Yates. Last year, I concluded my series of articles outlining the challenges and opportunities for pharma in the “MINT” countries, by stating ... Whilst the private sector represents the greatest
Is MINT the next BRIC?

Earlier this year, O’Neill came out of retirement to generate buzz about ‘MINT’ – that’s Mexico, Indonesia, Nigeria and Turkey to the uninitiated – as the next generation ‘ones to watch’ ... We will continue to monitor the MINT market,
Exploring MINT: Part 4 - Turkey

Turkey. Why Turkey? With a population of approximately 75 million, Turkey has the smallest population of all of the ‘MINT’ markets. ... As a result the greatest opportunities for pharma, within the MINT markets, at this stage often lie within the
Exploring MINT: Part 3 - Nigeria

From a healthcare perspective, Nigeria has some parallels with the other MINT markets of Mexico and Indonesia. ... Given the infrastructural, political and fiscal challenges, Nigeria’s potential may also take longer to realise, relative to the other